カテゴリ： GlobalData, アメリカ, 企業調査

AntriaBio Inc (ANTB)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：AntriaBio Inc (ANTB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013156
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月27日
◆ページ数：59
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
AntriaBio Inc (AntriaBio), formerly AntriaBio Delaware Inc is a biopharmaceutical company that develops drug therapies for the treatment of diabetes and metabolic diseases. The company’s lead product candidate include AB10, human recombinant insulin for use in type 1 and type 2 diabetes for the control of hyperglycemia; and AB301, a human glucagon-like peptide-1 agonist for the treatment of patients with type 2 diabetes. It also offers AB402, for vision-threatening eye complications of diabetes, including diabetic retinopathy and diabetic macular edema; and AB602, for the treatment of hereditary angioedema which are in preclinical studies. The company develops new product candidates by proprietary formulation and manufacturing capabilities. AntriaBio is headquartered in Louisville, Colorado, the US.

AntriaBio Inc (ANTB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
AntriaBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
AntriaBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
AntriaBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
AntriaBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
AntriaBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
AntriaBio Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
AntriaBio Raises USD6.7 Million in Venture Financing 13
AntriaBio Raises USD3.4 Million in Venture Financing 14
AntriaBio Raises US$7.3 Million In Venture Financing 15
Antriabio Raises US$1.8 Million In Venture Financing 16
Merger 17
AntriaBio And Fits My Style Complete Merger 17
Licensing Agreements 18
AntriaBio Enters into Licensing Agreement with ActiveSite Pharma 18
AntriaBio Enters into Licensing Agreement with pH Pharma 19
Equity Offering 20
AntriaBio Plans to Raise up to USD13.7 Million in Public Offering of Shares 20
AntriaBio Raises USD12.8 Million in Private Placement of Shares 21
AntriaBio Raises USD4.5 Million in Private Placement of Shares 22
AntriaBio Raises USD1.55 Million in Private Placement of Shares 23
AntriaBio Raises USD2.22 Million in Private Placement of Shares 24
AntriaBio Plans to Raise Funds through Public Offering of Shares 25
AntriaBio Raises USD0.1 Million in Private Placement of Shares 26
AntriaBio Raises USD2.23 Million in Private Placement of Shares 27
AntriaBio Raises USD0.46 Million in Private Placement of Shares 28
AntriaBio Raises USD12 Million in Private Placement of Shares and Warrants 29
AntriaBio Raises USD0.8 Million in Private Placement of Shares 30
AntriaBio Raises USD3.3 Million in Private Placement of Shares 31
AntriaBio Raises USD0.1 Million in Private Placement of Shares 32
AntriaBio Raises USD1 Million in Private Placement of Series A Preferred Stock 33
AntriaBio Raises USD6.4 Million in Private Placement of Shares 34
AntriaBio Raises USD3.34 Million in Private Placement of Shares 35
AntriaBio Raises USD2 Million in Private Placement of Series A Preferred Stock 36
AntriaBio Raises USD1.4 Million in Private Placement of Shares 37
AntriaBio Raises USD0.5 Million in Private Placement of Shares 38
AntriaBio Raises USD1.6 Million in Private Placement of Shares 39
AntriaBio Raises USD0.6 Million in Private Placement of Shares 40
AntriaBio Raises USD7 Million in Private Placement of Units 41
AntriaBio Raises USD3.62 Million in Private Placement of Shares 42
AntriaBio Raises USD3.2 Million in Private Placement of Shares 43
AntriaBio Completes First Tranche Of Private Placement Of Units For US$10 Million 44
AntriaBio Announces Private Placement Of Shares For US$12 Million 45
Acquisition 46
AntriaBio Acquires PR Pharma 46
AntriaBio Inc – Key Competitors 47
AntriaBio Inc – Key Employees 48
AntriaBio Inc – Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 50
Corporate Communications 50
Oct 09, 2017: AntriaBio Appoints Nektar Therapeutics CFO to its Board of Directors 50
Oct 04, 2017: AntriaBio Appoints Dr. Robert Bhisitkul to its Scientific Advisory Board 51
Product News 52
03/22/2017: Antriabio Appoints Two Pharmaceutical Executives To Its Board Of Directors 52
Product Approvals 53
Jun 05, 2017: AntriaBio Files Investigational New Drug Application for Once-Weekly Basal Insulin AB101 53
Clinical Trials 54
Oct 17, 2017: AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor AB-402 Candidate for Treatment of DR and DME 54
Oct 17, 2017: AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor AB-602 Candidate for Treatment of HAE 55
May 01, 2017: AntriaBio Formally Engages CRO for the Conduct of its Phase I First-in-Human Clinical Trial of AB101 56
Jun 22, 2016: AntriaBio Announces Preclinical Proof of Concept for Once-Weekly Basal Insulin AB101 in Diabetic Miniature Swine 57
Other Significant Developments 58
Sep 22, 2016: AntriaBio Announces Formation of Subsidiary and Plan to Raise Capital in South Korea 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
AntriaBio Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
AntriaBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
AntriaBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
AntriaBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
AntriaBio Inc, Deals By Therapy Area, 2011 to YTD 2017 10
AntriaBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
AntriaBio Raises USD6.7 Million in Venture Financing 13
AntriaBio Raises USD3.4 Million in Venture Financing 14
AntriaBio Raises US$7.3 Million In Venture Financing 15
Antriabio Raises US$1.8 Million In Venture Financing 16
AntriaBio And Fits My Style Complete Merger 17
AntriaBio Enters into Licensing Agreement with ActiveSite Pharma 18
AntriaBio Enters into Licensing Agreement with pH Pharma 19
AntriaBio Plans to Raise up to USD13.7 Million in Public Offering of Shares 20
AntriaBio Raises USD12.8 Million in Private Placement of Shares 21
AntriaBio Raises USD4.5 Million in Private Placement of Shares 22
AntriaBio Raises USD1.55 Million in Private Placement of Shares 23
AntriaBio Raises USD2.22 Million in Private Placement of Shares 24
AntriaBio Plans to Raise Funds through Public Offering of Shares 25
AntriaBio Raises USD0.1 Million in Private Placement of Shares 26
AntriaBio Raises USD2.23 Million in Private Placement of Shares 27
AntriaBio Raises USD0.46 Million in Private Placement of Shares 28
AntriaBio Raises USD12 Million in Private Placement of Shares and Warrants 29
AntriaBio Raises USD0.8 Million in Private Placement of Shares 30
AntriaBio Raises USD3.3 Million in Private Placement of Shares 31
AntriaBio Raises USD0.1 Million in Private Placement of Shares 32
AntriaBio Raises USD1 Million in Private Placement of Series A Preferred Stock 33
AntriaBio Raises USD6.4 Million in Private Placement of Shares 34
AntriaBio Raises USD3.34 Million in Private Placement of Shares 35
AntriaBio Raises USD2 Million in Private Placement of Series A Preferred Stock 36
AntriaBio Raises USD1.4 Million in Private Placement of Shares 37
AntriaBio Raises USD0.5 Million in Private Placement of Shares 38
AntriaBio Raises USD1.6 Million in Private Placement of Shares 39
AntriaBio Raises USD0.6 Million in Private Placement of Shares 40
AntriaBio Raises USD7 Million in Private Placement of Units 41
AntriaBio Raises USD3.62 Million in Private Placement of Shares 42
AntriaBio Raises USD3.2 Million in Private Placement of Shares 43
AntriaBio Completes First Tranche Of Private Placement Of Units For US$10 Million 44
AntriaBio Announces Private Placement Of Shares For US$12 Million 45
AntriaBio Acquires PR Pharma 46
AntriaBio Inc, Key Competitors 47
AntriaBio Inc, Key Employees 48
AntriaBio Inc, Subsidiaries 49

★海外企業調査レポート[AntriaBio Inc (ANTB)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • BELECTRIC GmbH：電力：M&Aディール及び事業提携情報
    Summary Belectric GmbH (Belectric) is a renewable energy company that offers solar systems and solutions. The company manufactures, designs, and constructs photovoltaic rooftop installation systems for solar-projects and ground-mounted solar power plants. It manufactures BoS components, photovoltaic …
  • Pharma Mar SA (PHM)-製薬・医療分野：企業M&A・提携分析
    Summary Pharma Mar SA (Pharma Mar) is a biopharmaceutical company that discovers, develops and markets marine-derived drugs to treat cancer. The company’s marketed product Yondelis (trabectedin), a novel, multimodal, synthetically produced antitumor agent, is indicated for the treatment of advanced …
  • Terramin Australia Ltd：企業の戦略・SWOT・財務分析
    Terramin Australia Ltd - Strategy, SWOT and Corporate Finance Report Summary Terramin Australia Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Naftna industrija Srbije ad (NIIS)：石油・ガス：M&Aディール及び事業提携情報
    Summary Naftna industrija Srbije ad (NIS), a subsidiary of Gazprom Neft, is an integrated energy company that conducts oil and gas exploration, production and refining, and sales and distribution of a broad range of petroleum products. Its refined products include motor fuel, diesel fuel, heating oi …
  • Illinois Municipal Electric Agency：企業の戦略的SWOT分析
    Illinois Municipal Electric Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Marriott Vacations Worldwide Corporation：企業の戦略・SWOT・財務情報
    Marriott Vacations Worldwide Corporation - Strategy, SWOT and Corporate Finance Report Summary Marriott Vacations Worldwide Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • IMI plc：企業の戦略・SWOT・財務分析
    IMI plc - Strategy, SWOT and Corporate Finance Report Summary IMI plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • EndoCeutics Inc-製薬・医療分野：企業M&A・提携分析
    Summary EndoCeutics Inc (EndoCeutics) is a pharmaceutical company that develops hormone sensitive cancer prevention therapies for women’s health. The company's pipeline product portfolio includes drugs for various indications such as endometriosis; male hypogonadism and antiandrogens, among others. …
  • Otter Tail Corp (OTTR)：企業の財務・戦略的SWOT分析
    Otter Tail Corp (OTTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Angelini Group：企業の戦略的SWOT分析
    Angelini Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Huge China Holdings Limited (428)：企業の財務・戦略的SWOT分析
    Huge China Holdings Limited (428) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Sonic Healthcare Limited：企業の戦略・SWOT・財務分析
    Sonic Healthcare Limited - Strategy, SWOT and Corporate Finance Report Summary Sonic Healthcare Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Baoviet Holdings
    Baoviet Holdings - Strategy, SWOT and Corporate Finance Report Summary Baoviet Holdings - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Murray & Roberts Holdings Ltd (MUR)：企業の財務・戦略的SWOT分析
    Murray & Roberts Holdings Ltd (MUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Ambrx Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Ambrx Inc (Ambrx) is a biopharmaceutical company that offers discovery and development of protein-based medicines by using its expanded genetic code. The company provides pipeline product candidate’s portfolio such as ARX618 FGF21, PSMA ADC, CD70 ADC and Anti-CD3 X Folate. It develops pipeli …
  • Mapletree Investments Pte Ltd：企業の戦略的SWOT分析
    Mapletree Investments Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Host Hotels & Resorts Inc (HST)：企業の財務・戦略的SWOT分析
    Host Hotels & Resorts Inc (HST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Abbott Laboratories (ABT)：医療機器：M&Aディール及び事業提携情報
    Summary Abbott Laboratories (Abbott) develops, manufactures, and sells a diversified range of healthcare products including drugs, diagnostics, branded generics, and vascular and nutritional products. The company’s products comprise specialized medicines; medical diagnostic instruments and tests; mi …
  • Chr. Hansen Holding AS (CHR)：企業の財務・戦略的SWOT分析
    Chr. Hansen Holding AS (CHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Estel Technologies Pvt. Ltd：企業の戦略的SWOT分析
    Estel Technologies Pvt. Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆